US equities |
MU $1,034.67 ▼-4.90% NVDA $230.38 ▼-2.99% SNDK $1,600.57 ▼-5.43% AMD $614.13 ▼-4.91% INTC $106.07 ▼-6.23% SPCX $162.00 ▼-3.34% META $719.41 ▼-0.26% MSFT $521.52 ▼-1.56%
FinancialContent

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.96 +0.46 (+2.66%)
Delayed Quote Updated: 3:09 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
36 37 Next >
News headline image
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. 
Via Investor's Business Daily
News headline image
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗
The threat is still emerging, but it could be significant. 
Via The Motley Fool
News headline image
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
News headline image
Got $1,000? Buy These Hot Growth Stocks Before They Take Off. ↗
These stocks haven't been able to get much traction lately, even though they clearly deserve to now. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst ↗
The upcoming regulatory decision on its latest drug could be big. 
Via The Motley Fool
News headline image
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
A Preview Of Sarepta Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript ↗
SRPT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Is It Too Late to Buy Sarepta Therapeutics Stock? ↗
The company's hyperfocus on its core area could continue to be highly lucrative. 
Via The Motley Fool
News headline image
Earnings Scheduled For February 28, 2024 ↗
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
News headline image
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices ↗
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight ↗
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024. 
Via Benzinga
News headline image
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter. 
Via Benzinga
News headline image
Why Sarepta Therapeutics Stock Is Soaring Today ↗
The biotech just scored a big FDA win with an even bigger one potentially coming by June. 
Via The Motley Fool
News headline image
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Magnificent Growth Stocks to Buy With $500 ↗
No need to break the bank to invest in promising stocks. 
Via The Motley Fool
News headline image
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
News headline image
Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst ↗
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. 
Via Benzinga
News headline image
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? ↗
Bad news for one player does not always equal good news for another. 
Via The Motley Fool
News headline image
Decoding Bearish Analog And The Warning Signs You Can't Ignore ↗
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
36 37 Next >